Oxidative mechanisms and tardive dyskinesia

CNS Drugs

Volumn 17, Issue 1, 2003, Pages 47-62

  Lohr, James B ^a,b   Kuczenski, Ronald ^a   Niculescu, Alexander B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; ESTRADIOL; EXCITOTOXIN; FLUPHENAZINE DECANOATE; FREE RADICAL; GINKGO BILOBA EXTRACT; HALOPERIDOL; IDEBENONE; INSULIN; LITHIUM; MELATONIN; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; REACTIVE OXYGEN METABOLITE; RISPERIDONE; SELEGILINE; UBIDECARENONE; VALPROIC ACID; ZIPRASIDONE;

ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; META ANALYSIS; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FREE RADICALS; HUMANS; VITAMIN E;

EID: 0037223482     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317010-00004     Document Type: Review

References (99)

1. Lohr JB, Jeste DV. Neuroleptic-induced movement disorders: Acute and subacute disorders. In: Cavenar Jr JO, editor. Psychiatry. Philadelphia (PA): Lippincott, 1988:1-19
2. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 61 Suppl. 4: 21-6
3. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756-65
4. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: Epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363-84
5. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196: 326-8
6. Rubinstein M, Muschietti JP, Gershanik O, et al. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J Pharmacol Exp Ther 1990; 252: 810-6
7. Klawans HL, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 1972; 33: 235-46
8. Lohr JB, Jeste DV. Neuroleptic-induced movement disorders: Tardive dyskinesia and other tardive syndromes. In: Cavenar Jr JO, editor. Psychiatry. Philadelphia (PA): Lippincott, 1988: 1-17
9. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000; 34: 355-69
10. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders: Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989; 570: 176-85
11. Fibiger HC, Lloyd KG. Neurohiological substrates of tardive dyskinesia: The GABA hypothesis. Trends Neurosci 1984; 7: 462-4
12. Sachdev P, Saharov T, Cathcart S. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol Psychiatry 1999; 46: 1672-81
13. Elkashef AM, Wyatt RJ. Tardive dyskinesia: Possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999; 25: 731-40
14. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-95
15. Hensley K, Floyd RA. Reactive oxygen species and protein oxidation in aging: A look back, a look ahead. Arch Biochem Biophys 2002; 397: 377-83
16. Wickens AP. Ageing and free radical theory. Respir Physiol 2001; 128: 379-91
17. Kesavulu MM, Rao BK, Giri R. et al. Lipid peroxidation and antioxidant enzyme status in type 2 diabetics with coronary heart disease. Diabetes Res Clin Pract 2001; 53: 33-9
18. Duhey RK, Tyurina YY, Tyurin VA, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res 1999; 84: 229-39
19. Zima T, Fialova L, Mestek O, et al. Oxidative stress, metabolism of ethanol and alcohol-related diseases. J Biomed Sci 2001; 8: 59-70
20. Mantle D, Preedy VR. Free radicals as mediators of alcohol toxicity. Adverse Drug React Toxicol Rev 1999; 18: 235-52
21. Mercuri F, Quagliaro L, Ceriello A. Oxidative stress evaluation in diabetes. Diabetes Technol Ther 2000; 2: 589-600
22. Turrone P, Seeman MV, Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry 2000; 45: 288-90
23. Grace AA, Bunney BS, Moore H, et al. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 1997; 20: 31-7
24. Schultz SK, Miller DD, Arndt S, et al. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biol Psychiatry 1995; 38: 713-9
25. Ahmed S, Chengappa KN, Naidu VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: A case series. J Clin Psychiatry 1998; 59: 472-7
26. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Clarendon Press, 1985
27. Acuna-Castroviejo D, Martin M, Macias M, et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30: 65-74
28. Lohr JB. Oxygen radicals and neuropsychiatric illness: Some speculations. Arch Gen Psychiatry 1991; 48: 1097-106
29. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344: 796-8
30. Beal MF. Aging, energy, and oxidative stress in neurodegenerative disease. Ann Neurol 1995; 38: 357-66
31. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999; 222: 236-45
32. Bird ED, Collins GH, Dodson MH, et al. The effect of phenothiazine on the manganese concentration in the basal ganglia of sub-human primates. In: Barbeau A. Burnette J-R, editors. Progress in Neuro-genetics. Amsterdam: Excerpta Medica, 1967: 600-5
33. Weiner WJ, Nausieda PA, Klawans HL. Effect of chlorpromazine on central nervous system concentrations of manganese, iron, and copper. Life Sci 1977; 20: 1181-6
34. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 71: 1002-12
35. Galili-Mosberg R, Weizman A, Melamed E, et al. Haloperidol-induced neurotoxicity: Possible implications for tardive dyskinesia. J Neural Transm 2000; 107: 479-90
36. Murthy JN, Laev H, Karpiak S, et al. Enzymes of oxyradical metabolism after haloperidol treatment in rat [abstract]. Soc Neurosci Abstracts 1989; 15: 139
37. Cadet JL, Perumal AS. Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 1990; 28: 738-40
38. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26: 689-90
39. Shivakumar BR, Ravindranath V. Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res 1992; 595: 256-62
40. Tsai G, Goff D, Chang RW, et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155: 1207-13
41. Behl C, Rupprecht R, Skutella R, et al. Haloperidol-induced cell death: Mechanism and protection with vitamin E in vitro. Neuroreport 1995; 7: 360-4
42. Post A, Holsboer F, Behl C. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: Suppression of NF-κB and neuroprotection by antioxidants. J Neurosci 1998; 18: 8236-46
43. Burkhardt C, Kelly JP, Lim YH, et al. Neuroleptic medications inhibit complex 1 of the electron transport chain. Ann Neurol 1993; 33: 512-7
44. Prince JA, Hassin MS, Oreland L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J Pharmacol Exp Ther 1997; 280: 261-7
45. Maurer I, Moller HJ. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 1997; 174: 255-9
46. Hori H, Ohmori O, Shinkai T, et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia. Psychopharmacology (Berl) 2000; 23: 170-7
47. Gattaz WF, Emrich A, Behrens S. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: Possible implications for tardive dyskinesia. J Neural Transm 1993; 92: 197-201
48. Lohr JB, Caligiuri MP, Manley MS, et al. Neuroleptic-induced striatal damage in rats: A study of antioxidant treatment using accelerometric and immunocytochemical methods. Psychopharmacology (Berl) 2000; 148: 171-9
49. Hunter R, Blackwood W, Smith MC, et al. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci 1968; 7: 263-73
50. Campbell WG, Raskind MA, Gordon T, et al. Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry 1985; 142: 364-5
51. Bartzokis G, Garber HJ, Marder SR, et al. MRI in tardive dyskinesia: Shortened left caudate T2. Biol Psychiatry 1990; 28: 1027-36
52. Casanova MF, Comparini SO, Kim RW, et al. Staining intensity of brain iron in patients with schizophrenia: A postmortem study. J Neuropsychiatry Clin Neurosci 1992; 4: 36-41
53. Pall HS, Williams AC, Blake DR, et al. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; II: 596-9
54. Pai BN, Janakiramaiah N, Gangadhar BN, et al. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 1994; 36: 489-91
55. Lohr JB, Kuczenski R, Bracha HS, et al. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 28: 535-9
56. National Institute of Mental Health. Abnormal involuntary movement scale. In: Guy W, editor. Early Clinical Evaluation Unit Assessment Manual. Rockville (MD): US Department of Health and Human Services, 1976: 534-7
57. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982; 39: 486-7
58. Peet M, Laugharne J, Rangarajan N, et al. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993; 8: 151-3
59. McCreadie RG, MacDonald E, Wiles D, et al. The Nithsdale schizophrenia surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br J Psychiatry 1995; 167: 610-7
60. Goff DC, Tsai G, Beal MF, et al. Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry 1995; 152: 1730-6
61. Brown K, Reid A, White T, et al. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 1998; 43: 863-7
62. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatr Res 1998; 80: 29-39
63. Abdalla DSP, Manteiro HP, Olivera JAC, et al. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem 1986; 32: 805-7
64. Yao JK, Reddy R, McElhinny LG, et al. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998; 32: 385-91
65. Gattaz WF. Does vitamin E prevent tardive dyskinesia? Biol Psychiatry 1995; 37: 895-7
66. Dorfman-Etrog P, Hermesh H, Prilipko L, et al. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: An open label study. Eur Neuropsychopharmacol 1999; 9: 475-7
67. Crane GE. Pseudoparkinsonism and tardive dyskinesia. Arch Neurol 1972; 27: 426-30
68. Caligiuri MP, Lohr JB, Bracha HS, et al. Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia. Biol Psychiatry 1991; 29: 139-48
69. Lohr JB, Cadet JL, Lohr MA, et al. Alpha-tocopherol in tardive dyskinesia: A preliminary study. Lancet 1987; 1: 913-4
70. Lohr JB, Cadet JL, Lohr MA, et al. Vitamin E in the treatment of tardive dyskinesia: The possible involvement of free radical mechanisms. Schizophr Bull 1988; 14: 291-6
71. Elkashef AM, Ruskin PE, Bacher N, et al. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990; 147: 505-6
72. Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E. Eur Psychiatry 1991; 6: 201-7
73. Egan MF, Hyde T, Albers G, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149: 773-7
74. Shriqui CL, Bradwejn J, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study. Am J Psychiatry 1992; 149: 391-3
75. Spivak B, Schwartz B, Radwan M, et al. Alpha-tocopherol treatment for tardive dyskinesia. J Nerv Ment Dis 1992; 180: 400-1
76. Junker D, Steigleider P, Gattaz WF. Alpha-tocopherol in the treatment of tardive dyskinesia. Clin Neuropharmacol 1992; 15 (Suppl. 1, Pt b): 639B
77. Akhtar S, Jajor TR, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 1993; 39: 124-6
78. Adler L, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405-7
79. Lam LCW, Chiu HFK, Hung SF. Vitamin E in the treatment of tardive dyskinesia: A replication study. J Nerv Ment Dis 1994; 182: 113-4
80. Dabiri LM, Pasta D, Darby JK, et al. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994; 151: 925-6
81. Lohr JB, Caligiuri MP. A double-blind placebo controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57: 167-73
82. Dorevitch A, Kalian M, Shlafman M, et al. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 1997; 41: 114-6
83. Sajjad SHA. Vitamin E in the treatment of tardive dyskinesia: A preliminary study over 7 months at different doses. Int Clin Psychopharmacol 1998; 13: 147-55
84. Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998; 43: 868-72
85. Barak Y, Swartz M, Shamir E, et al. Vitamin E (α-tocopherol) in the treatment of tardive dyskinesia: A statistical meta-analysis. Ann Clin Psychiatry 1998; 10: 101-5
86. Soares KVS, McGrath JJ. The treatment of tardive dyskinesia: A systematic review and meta-analysis. Schiz Res 1999; 39: 1-16
87. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry 1999; 56: 836-41
88. Lohr JB, Lavori P. Whither vitamin E and tardive dyskinesia? Biol Psychiatry 1998; 43: 861-2
89. Goff DC, Renshaw PF, Sarld-Segal O, et al. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 1993; 33: 700-6
90. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001; 58: 1049-52
91. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: Implications for tardive dyskinesia? Prog Neurobiol 2000; 61: 525-41
92. Zeevalk GD, Bernard LP, Nicklas WJ. Oxidative stress during energy impairment in mesencephalic cultures is not a downstream consequence of a secondary excitotoxicity. Neuroscience 2000; 96: 309-16
93. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: A retrospective analysis of 1027 patients. Psychopharmacol Bull 1997; 33: 177-81
94. Harvey BH, Bester A. Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav Brain Res 2000; 111: 203-11
95. Bolkenius FN, Verne-Mismer J, Wagner J, et al. Amphiphilic α-tocopherol analogues as inhibitors of brain lipid peroxidation. Eur J Pharmacol 1996; 298: 37-43
96. Kitani K, Minami C, Yamamoto T, et al. Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: A possible antioxidant strategy. Ann N Y Acad Sci 2001; 928: 248-60
97. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia: The North American EGb Study Group. JAMA 1997; 278: 1327-32
98. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study. J Neural Transm Suppl 1998; 54: 301-10
99. McGrath JJ, Soares KV. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. The cochrane database of systematic reviews. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Oxford Update Software, 2000